China’s rapidly growing economy has helped drive unprecedented growth in its healthcare market. Driven by pro-innovation and pro-biotechnology policy trends, China is becoming a prime market for biopharmaceutical companies globally; nearly 90% of the firms in L.E.K.’s biopharma survey expressed interest in a China expansion. Furthermore, Asia, not only contains 60 percent of the world’s population, it also accounts for 30% of the world’s GDP and pharmaceutical spending.  

While recent policy reforms in China are expected to create enormous opportunities for global firms, China nevertheless remains a complicated market for emerging biotech companies and multinational corporations alike. 

This Special Report highlights the potential opportunities, entry approaches and local partner selection, and also include recommendations on market acceleration and internationalization.

Related Insights